Anti-Human IGF1R (CD221) (Teprotumumab) [Clone RG1507] (I-2210-25mg)

The insulin-like growth factor-1 receptor (IGF1R) is a key receptor tyrosine kinase that regulates cell growth, proliferation, and survival, playing a critical role in cancer development and progression. Overexpression of IGF1R is commonly observed in various cancers, where it promotes tumor growth, transformation, motility, and metastasis. Targeting IGF1R has become a promising therapeutic approach, with strategies including the reduction of receptor expression, inhibition of kinase activity through small-molecule inhibitors, disruption of receptor function using monoclonal antibodies, and neutralization of its ligands. A deeper understanding of the downstream signaling pathways and IGF1R's role in different cancer types is essential for developing more effective treatments1,2. Teprotumumab has shown significant potential, particularly in the treatment of thyroid eye disease (TED). Its effectiveness stems from its ability to inhibit IGF1R, which is linked to the thyrotropin receptor, a central factor in TED's pathology. However, teprotumumab therapy is associated with side effects such as hyperglycemia, hearing changes, fatigue, muscle spasms, hair loss, weight loss, gastrointestinal issues, menstrual irregularities, and infusion reactions. Recognizing and managing these adverse effects is crucial for optimizing teprotumumab’s use in clinical practice, ensuring a favorable balance between its risks and benefits3,4.